IQV

IQVIA Holdings Inc.

$267.85

+0.74% 2026-10-20

Health CareS&P 500

1M 3M 6M 1Y 2Y

IQVSPY

+2.8%

+0.5%

+32.8%

+52.5%

YTD

+18.8%

+26.3%

Live chart

Loading live chart…

Grades vs sector

Momentum

58th pct in sector

B-

12-1 return: +24.2%
Percentile within its GICS sector across the S&P 1500.

Growth

51st pct in sector

C+

Revenue growth (YoY): +8.7%
Percentile within its GICS sector across the S&P 1500.

Value

40th pct in sector

C-

Forward E/P: 5.4% · EBITDA/EV: 5.2%
Percentile within its GICS sector across the S&P 1500.

Profitability

65th pct in sector

Profit margin: +8.1% · Return on equity: +22.8%
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Top 15

rank 108 of 499 · 12-1 momentum % 37.5

Momentum Blend

not in the current book

New Highs Growth

not ranked (outside this model's universe or screens)

Conviction 20

not in the current book

News

More news

IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?

Zacks · 15h ago

Should You Be Worried About Tempus AI Stock?

Trefis · 17h ago

1 Large-Cap Stock to Research Further and 2 We Avoid

StockStory · Oct 19

BMO Capital Adjusts Price Target on IQVIA to $305 From $270

MT Newswires · Oct 19

3 Low-Volatility Stocks with Questionable Fundamentals

StockStory · Oct 16

Key stats

Market cap$44.1B

P/E (trailing)33.3

P/E (forward)18.6

52-week range154.50 – 277.40

Revenue growth (YoY, latest qtr)+8.7%

Dividend yield0.00%

Analyst consensusStrong Buy (19)

Mean price target$300.95 (+12%)

Valuation and fundamentals

Valuation & fundamentals

Bottom line

Looks expensive

Model read-out from the numbers below, not advice. Score -3 (DCF counts double).

▼DCF (base case)below the price by 29%

•Forward P/E vs sector18.6x vs median 17.6x

•Piotroski F-score5/9

•Altman Z2.2 (grey)

▼Net debt / EBITDA4.1x

•Analyst target+12% (19 analysts)

Discounted cash flow

Bear

$95

-65%

growth 1% · disc. 11.1% · term. 2.0%

Base

$191

-29%

growth 6% · disc. 10.1% · term. 2.5%

Bull

$315

+18%

growth 9% · disc. 9.1% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Today's price assumes free cash flow grows about 9% a year for 10 years.

Implied

+9%/yr

FCF, last 3 yrs

+6%/yr

FCF, last 5 yrs

+6%/yr

Revenue, last 3 yrs

+4%/yr

Revenue, last 5 yrs

+8%/yr

Same inputs as the DCF above: trailing free cash flow 2.7B, 10.1% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-03-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.17 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9× · 56th pct

33.3×
pricier

Forward P/E

sector median 17.6× · 56th pct

18.6×
pricier

EV / EBITDA

sector median 15.8× · 58th pct

17.2×
pricier

Price / sales

sector median 3.1× · 43rd pct

2.7×
cheaper

Price / book

sector median 3.5× · 79th pct

7.1×
pricier

FCF yield

sector median 4.1% · 77th pct

6.1%
cheaper

Forward EPS $14.41 vs trailing $8.05 (+79% expected growth). Forward P/E uses analysts' next-12-month estimate.

Backlog (remaining performance obligations)

RPO

$37.3B

as of 2026-03-31

vs a year ago

+7%

YoY

× TTM revenue

2.24×

coverage

24-06

24-09

24-12

25-03

25-06

25-09

25-12

26-03

Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).

Quality & financial health

Gross margin

–

Operating margin

13.2%

FCF margin

16.3%

Net margin

8.3%

Return on equity

22.3%

Return on invested capital

9.3%

Net debt / EBITDA

4.1×

Current ratio

0.7×

Interest cover

2.9×

Cash conversion (OCF/NI)

2.0×

Piotroski F-score 5/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✗ Gross margin improved✗ Asset turnover improved

Altman Z-score 2.2 (grey zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$301

+12%

Analysts

Strong Buy

Range

$268–$345

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$16.3B	$1.4B	$2.7B
2024	$15.4B	$1.4B	$2.7B
2023	$15.0B	$1.4B	$2.1B
2022	$14.4B	$1.1B	$2.3B
2021	$13.9B	$966.0M	$2.9B
2020	$11.4B	$279.0M	$2.0B

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +4.2%.

Earnings

Next report: 2026-10-27 · before open · EPS est 3.27

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-07-28	3.03	3.15	+3.9%
2026-05-05	2.82	2.90	+3.0%
2026-02-05	3.40	3.42	+0.7%
2025-10-28	2.98	3.00	+0.8%
2025-07-22	2.77	2.81	+1.4%
2025-05-06	2.63	2.70	+2.6%
2025-02-06	3.11	3.12	+0.4%
2024-10-31	2.81	2.84	+1.0%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$4.4B	+8.7%
2026-03-31	$4.2B	–
2025-12-31	$4.4B	–
2025-09-30	$4.1B	–
2025-06-30	$4.0B	–

Analyst actions

Stifel

2026-10-14 · main

Buy → Buy
PT $303

Mizuho

2026-10-07 · main

Outperform → Outperform
PT $300

Barclays

2026-10-07 · main

Overweight → Overweight
PT $300

RBC Capital

2026-09-29 · main

Outperform → Outperform
PT $319

Truist Securities

2026-09-28 · reit

Buy → Buy
PT $329

Morgan Stanley

2026-09-17 · main

Equal-Weight → Equal-Weight
PT $270

Insider trades

Berkshire James G.

See Remarks · 2026-09-02

SELL
$697.2K

Staub W Richard

See Remarks · 2026-08-03

SELL
$1.3M

Patel Bhavik

See Remarks · 2026-07-31

SELL
$436.4K

Sherbet Eric

See Remarks · 2026-07-29

SELL
$1.2M

Cherofsky Keriann

See Remarks · 2026-07-29

SELL
$136.8K

Bousbib Ari

Director, See Remarks · 2026-07-29

SELL
$1.1M

Bousbib Ari

Director, See Remarks · 2026-07-29

SELL
$1.1M

Bousbib Ari

Director, See Remarks · 2026-07-29

SELL
$10.8M

Bousbib Ari

Director, See Remarks · 2026-07-29

SELL
$13.0M

Stats refreshed 2026-10-20 18:08:40 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.

How it works Disclaimer Terms Privacy Data status